Type 2 diabetes Oxidative stress 8-oxo-7 8-dihydroguanosine 8-oxo-7 8-dihydro-2-deoxyguanosine Clinical markers Diabetic complications
expectancy but the disease leads to severe complications, negatively affecting quality of life [3] . Even though mortality and morbidity has improved over the last decades [4] , the increased diabetes prevalence warrants continued improvement of diabetes care [3] .
The Steno-2 study has had considerable effect on type 2 diabetes treatment worldwide [5, 6] . In the Steno-2 study intensified multifactorial treatment compared with conventional multifactorial treatment cut by half morbidity and mortality in T2D patients with microalbuminuria and increased complications free length of life by approximately eight years [5, 7] .
However, current treatment strategies are limited by means of not being able to predict which patients will need intensified treatment [8] . Thus, despite an agreement of intensified multifactorial treatment in type 2 diabetes, the remedies to tailor treatment for the individual patient await. In our attempt of pursuing this personal medicine approach, we have previously shown that RNA oxidation product 8-oxo-7,8-dihydroguanosine (8-oxoGuo) is prognostic for mortality and cardiovascular death in patients with type 2 diabetes [9] , but at present no approved treatments lowering urine 8-oxoGuo level exist. The biomarkers of DNA and RNA oxidation 8-oxoGuo and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) are considered as reliable biomarkers of oxidative stress in several human diseases [10, 11] . Oxidative stress is defined as an oxidants/antioxidants imbalance resulting in oxidants overproduction and causes cell signaling disruption and molecular damage depending on the extent [12, 13] . Accumulating evidence shows that oxidative stress is linked to the pathogenesis of diabetic vascular complications [14] [15] [16] [17] , and involves oxidative damage to e.g. DNA and RNA [18, 19] . Thus, altering nucleic acid oxidation levels could possibly better disease progression.
The objective of this study was to assess, in a post-hoc analysis, the association between urinary levels of 8-oxoGuo and all-cause mortality from advanced baseline to end of follow-up; up to 19.9 years, and from end of 7.8 years of intervention to end of follow-up; up to 13.9 years. For comparison, same analyses with DNA oxidation product 8-oxodG were performed since increased urinary 8-oxodG has been correlated with hyperglycemia and implicated in diabetic complications [20] .
Material and methods

Study population and design
Detailed information from the Steno-2 study on patient inclusion, randomisation, intervention and follow-up including anthropometric, physiological and biochemical measurements have previously been published [21] .
In short, in 1993, 160 patients with type 2 diabetes and microalbuminuria were randomised 1:1 to eight years of either intensified multifactorial treatment or conventional multifactorial treatment (control group).
At the advanced baseline (1995), urine samples from 155 subjects (97% of the patients) were available ( Fig. 1) . At the end of 7.8 years intervention (2001), 125 urine samples (96% of the patients alive) were available ( Fig. 1 ).
Study endpoints
For the assessment of the urinary nucleic acid oxidation biomarker risk analyses, we used all-cause mortality as outcome measure in pooled-cohort analyses from 1995 with up to 19.9 years of follow-up and from 2001 with up to 13.9 years of follow-up, respectively.
Measurement of urinary nucleic acid oxidation biomarkers
8-oxoGuo levels and 8-oxodG levels in urine samples were quantified by a validated method based on ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and corrected for urinary creatinine concentration [22] .
Previously published data from our laboratory showed a lower limit of quantification of 1.0 nM for both 8-oxoGuo and 8-oxodG, with an accuracy of 98.7% for 8-oxoGuo and 95.7% for 8-oxodG [22] . Average within-day precision was 2.9% for 8-oxoGuo and 3.7% for 8-oxodG; average between-day precision was 1.5% for 8-oxoGuo and 3.4% for 8-oxodG [22] . Specificity was determined by measuring quantifier and qualifier ions and using the relevant acceptance criteria for the response ratio between the two ions.
The analyses were performed in June 2017. The urine samples were stored at − 80°C until the time of analyses. At this time the urine samples were stored at − 20°C, which secure stable amount of the nucleic acid oxidation markers throughout 15 years [23] .
Ethics
The original Steno-2 study was in accordance with the declaration of Helsinki and approved by the local ethics committee (Ethics committee, Capital Region of Denmark; protocol ID number: H-KA-99035-GS, add. 41104) and the Danish Data Protection Agency (J.Nr. 2015-41-4042). The original trial was registered at Clinicaltrials.gov, number NCT00320008. This post-hoc study was, in addition to the above, approved by the local ethics committee (H-16029199). All participants gave their informed consent before randomisation and again at each follow-up visit.
Statistics
For variables with Gaussian distribution, means were compared using t-test. For dichotomous variables, Chi-squared test were used to compare groups. Based on the Kaplan-Meier estimates, survival probability plots were drawn. Cox regression analyses were performed for the adjusted and stratified all-cause mortality estimations. 8-oxoGuo and 8-oxodG were used both as continuous variables (log2-transformed) and as categorical (dichotomized, cut-off at median; low vs. high RNA oxidation). Based on previous literature and availability of covariates, the final fully adjusted Cox regression model included adjustment for age, sex, treatment allocation, urinary albumin excretion ratio (AER), systolic blood pressure, total plasma cholesterol, and due to availability either waist-hip-ratio (WHR) in 1995 and body mass index (BMI) in 2001, respectively. Complete case analyses were conducted for log2-transformed models since one was missing in the multiple adjusted models (1 missing for WHR in 1995 and 1 missing for BMI in 2001, respectively). To ensure stable models, all models were fitted with 1000 bootstrap samples and considered stable. We tested the added value of RNA oxidation in the Cox regressions models with the area under the curve (AUC) and prediction error with the Brier score.
Furthermore, for the assessment of an intensified multifactorial treatment compared with conventional treatment on RNA oxidation in patients with type 2 diabetes and microalbuminuria on mortality, patients were stratified according to levels of RNA oxidation and intervention in a Cox regression model adjusted for age and sex. R version 3.4.1 was used to perform the statistical analyses [24] .
Results
Patients' characteristics according to nucleic acid oxidation marker levels
In 1995, median RNA oxidation level was 2.4nmol/mmol creatinine and median DNA oxidation level was 1.3nmol/mmol creatinine. No difference in nucleic acid oxidation marker levels was seen between the intensified and conventional treatment group.
In 1995, patients' characteristics were similar in the low and high RNA oxidation groups except for more women (33.8% vs. 17.9%, p = 0.04), higher HbA 1c (74.1 mmol/mol vs. 68.2 mmol/mol, p=0.04) (Table 1a) . Treatment allocation was not significantly different for high and low RNA oxidation group (p = 0.30). For DNA oxidation, no differences were seen between the low and high DNA oxidation group (Table 1b) . In 2001, median RNA oxidation level was 2.8nmol/mmol creatinine and median DNA oxidation level was 1.7nmol/mmol creatinine. No difference in levels or changes in nucleic acid oxidation marker levels was seen between the intensified and conventional treatment group.
In 2001, patients in the high versus in the low RNA oxidation group were older (mean=63 years vs. 61 years, p = 0.049), more were women (38.7% vs. 12.7%, p = 0.002) and diastolic blood pressure was slightly lower (mean=73 mmHg vs. 77 mmHg, p = 0.04; Table 2a ).
Still, allocation was not significantly different between high and low RNA oxidation group (p = 0.33).
For DNA oxidation, no differences were seen except for higher body weight in the high than in the low DNA oxidation group (mean=96.9 kg vs. 90.8 kg, p = 0.04; Table 2b ).
All-cause mortality pooled analyses for RNA oxidation
Urinary levels of RNA oxidation in 1995, after 2 years of intervention with following 19.9 years of follow-up, were not associated with mortality ( Fig. 2a and Table 3) .
From end of intervention in 2001, 7.8 years after baseline, with 13.9 years of follow-up, 38.1% compared with 59.7% in the low versus high Abbreviations: IQR, interquartile range.
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RNA oxidation group had died (log-rank test p = 0.02, Fig. 2c ). Both the unadjusted, age-and sex adjusted, and multiple adjusted cox regression analyses showed significantly higher hazard ratio (HR) for log2-transformed RNA oxidation (multiple adjusted HR 3.08 [1.86-5.12]; p-value < 0.001, Table 3 ).
All-cause mortality for RNA oxidation stratified for intervention
When stratifying according to intervention group in 1995 (Fig. 3a) , the lowest HR was seen for low RNA oxidation group receiving intensified treatment (age-and sex adjusted HR 0.40, 95% CI [0.21-0.75], p = 0.004; Fig. 4a) .
From 2001 to end of follow-up (Fig. 3b) , the low RNA oxidation group receiving intensified treatment had significantly lower HR compared to conventional treatment with high RNA oxidation (age-and sex adjusted HR 0.28, 95% CI [0.13 −0.61], p = 0.001; Fig. 4b ).
DNA oxidation survival analyses
For DNA oxidation, no difference in mortality was seen between low and high DNA oxidation (log-rank test p = 0.6, Figs. 2b and 2d).
Additional analyses
The added value of the urinary RNA oxidation biomarker 8-oxoGuo in the fully adjusted Cox regression model (2001) intervention in the fully adjusted Cox regression model were tested with ANOVA and was not significant (p = 0.18). Furthermore, we tested the same interactions in 1995 and found p = 0.03.
Discussion
In patients with type 2 diabetes and microalbuminuria we found that a high level of RNA oxidation after 7.8 years of intervention was associated with higher mortality after 13.9 years of follow-up.
For the first time, we have showed that low urinary RNA oxidation level after an intensified multifactorial treatment for 7.8 years is associated with lower mortality compared with high RNA oxidation after a conventional treatment. This was also seen after only 2 years intervention, but not as pronounced.
Type 2 diabetes is a multi-organ disease [25] , and as such, a wholebody biomarker like urinary RNA oxidation is straightforward as both a prognostic and predictive biomarker. While we have established urinary RNA oxidation as a prognostic biomarker [9, 26] , we believe this study is the first evidence of urinary RNA oxidation as a predictive biomarker in patients with type 2 diabetes.
To our knowledge, this is the first step towards finding treatments that decrease urinary RNA oxidation and improve survival. This finding also merits future examination of more specific pharmacological treatment regimens than in this study. The Steno-2 study design is too limited in size to enable analyses of each single component of the intervention. Moreover, the intensified treatment regimen included lifestyle changes including smoking cessation which could have altered the urinary nucleic acid oxidation markers. Impact of lifestyle intervention is seen for heart failure markers like NT-proBNP in the Look AHEAD study [27] , and a number of diabetic risk factors were decreased in the Diabetes Care in General Practice (DCGP) study which also included an intensified lifestyle intervention [28] .
In the redox research field, DNA oxidation has been given the major attention over the past decades whereas less thought has been given on RNA oxidation [29, 30] . Yet, RNA oxidation is increasingly being appreciated for its part in various diseases [29, 30] . It is now evident that imbalance or rather disturbed oxidative damage to RNA can be measured in urine and used as a biomarker for disease complications; exemplified in diabetic, neurological and psychiatric diseases [30, 31] . Oxidative damage to DNA measured as 8-oxodG was discovered in 1984 and later in vitro and in vivo experiments found that 8-oxoGuo was higher in RNA than 8-oxodG in DNA after inducement by agents [10, 11] . Plausible reasons for this difference between DNA and RNA include the double-stranded structure of DNA versus the singlestranded structure of RNA, the lack of protective proteins such as histones in DNA and repair enzymes which provide prompt removal of 8-oxoGua in DNA or maybe higher reactivity of reactive oxygen species (ROS) with RNA in the cytoplasm versus nuclear DNA [11, 32] . Moreover, the location of RNA in the cytoplasm in close proximity to the ROS-producing mitochondria versus nuclear DNA suggests that compartmentalization may also be of significance [31] . Although repair mechanisms may exist for RNA, degradation and elimination are currently the believed mechanisms [30, 31, 33] . We suggest that these reasons could explain the differences we and others see between RNA and DNA oxidation in patients with type 2 diabetes [9, 19, 26, 34] .
With this study, we indicate that a urinary RNA oxidation biomarker could be implemented in clinical trials to monitor treatment response and subsequent risk of diabetic late complications. Recently, an expert group emphasized the necessity of using the full biorepositories, highlighting the findings of new biomarkers, to achieve precision medicine onwards [35] . Perhaps this could contribute to transform the future diabetes care along with already improved reevaluations since FDA guidelines in 2008 prompted cardiovascular outcome safety trials [35] . * Age-, sex-and intervention-stratification gave similar results. ** Multiple models included adjustment for age, sex, albumin excretion rate (geometric mean), systolic blood pressure, allocation and either waist hip ratio (1995) or body mass index (2001). Fig. 3 . Survival probability according to low and high RNA oxidation markers stratified for intervention. Kaplan-Meier plot shows survival probability in 1995 onwards and 2001 onwards; for the conventional treatment, the black line shows low RNA oxidation = below the median and the red line shows high RNA oxidation = above the median; for the intensified treatment, the green line shows low RNA oxidation = below the median and the blue line shows high RNA oxidation = above the median. 
Strengths and limitations
The Steno-2 study is a unique study in many ways. First of all, only one patient was lost to follow-up because of emigration. Second of all, detailed long-term follow-up for up till 19.9 years since advanced baseline in 1995 and 21.1 years since enrollment in 1993 was available. Third of all, care of the intensified treatment arm was primarily carried out at the Steno Diabetes Center facility ensuring minimally variation compared with multi-facility studies.
Importantly, the Steno 2 cohort was a high-risk group with preexisting microalbuminuria. Therefore, these results may not be applicable to lower risk groups of patients with type 2 diabetes.
Due to availability, only urine samples for 155 patients (97%) in 1995 and urine samples for 125 patients (96% of subjects alive) in 2001 were used in this study. Since the Steno-2 study sample size was originally small further reductions in size warrant attention to the adjustments in the statistical models in this post-hoc study. We assured that our final models were stable; however, power issues or chance findings are likely to occur.
The median RNA oxidation and DNA oxidation was a little lower in this study compared with our previous cohort studies [9, 26] . In part, this could be explained by the fact that the urine samples were not morning spot urine but a sample of 24-h urine collection and thus more diluted. This was a post-hoc study and therefore was not designed to investigate the predictive potential of urinary RNA oxidation including the added value of the biomarker. These features should be investigated in a study with pre-specified power calculations.
Interestingly, we see that high RNA oxidation at the advanced baseline in 1995 was associated with diabetes risk factors such as macroalbuminuria and higher HbA 1c . These associations were attenuated in 2001. We speculate if this is due to the intervention, but this again require additional studies since no interactions were seen between RNA oxidation and intervention groups in our analyses in 2001. We did not see any difference between intervention groups in changes in RNA oxidation from available urine samples in 1995-2001, however, more patients died in the conventional treatment group than the intensified treatment group, and the patients who died plausible had higher RNA oxidation. The added value of the biomarker for RNA oxidation in our study showed a trend for better performance in the prediction models, but was not statistically significant. Moreover, since the model already showed good prediction accuracy before adding RNA oxidation, performance enhancement of the model was more difficult. Although this is in agreement with a previous study [26] , a larger study with high risk patients with type 2 diabetes is warranted to address the added value.
Conclusions
In T2D patients with microalbuminuria, urinary 8-oxoGuo level after 7.8 years of intensified multifactorial treatment was associated with total mortality during 13.9 years of post-trial follow-up. Patients allocated to intensified multifactorial treatment had lower risk of dying overall, and patients with low RNA oxidation in the intensified multifactorial treatment had the lowest risk of dying while patients with high RNA oxidation in conventional treatment had the highest risk of dying. These results are the first evidence of urine 8-oxoGuo as a predictive biomarker in patients with type 2 diabetes.
